Exclusive: Study in Brazil indicates Sinovac vaccine works against P1 variant found in Brazil - source
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
FILE PHOTO: A display shows vaccine products of Sinovac Biotech during a government-organized media tour showcasing the company's development of a coronavirus disease (COVID-19) vaccine candidate in Beijing, China, September 24, 2020. REUTERS/Thomas Peter
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SAO PAULO (Reuters) - Preliminary data from a study in Brazil indicates that the COVID-19 vaccine developed by China's Sinovac Biotech Ltd is effective against the P1 variant of the virus first discovered in Brazil, a source familiar with the study told Reuters on Monday.
The source, who did not provide data details, said the study had tested the blood of vaccinated people against the Brazilian variant of the virus. Coronavac, as the Sinovac shot is known, is the main vaccine currently being used to inoculate people in Brazil.
(Reporting by Eduardo Simoes; Writing by Stephen Eisenhammer; Editing by Bill Berkrot)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UAE is mediating between India and Pakistan, says senior diplomat
- German COVID-19 cases jump by most since early January
- TSMC books 19% Q1 profit growth; says chip shortage likely last into 2022